Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2194190. doi: 10.1080/21645515.2023.2194190. Epub 2023 Apr 26.
WHO-recommended vaccines substantially prevent and control vaccine-preventable diseases (VPDs), but their inclusion differs among countries and regions. We reviewed the application for WHO-recommended vaccines in China and described the concerns and obstacles in driving the inclusion of more vaccines into China's NIP, including immunization strategies, financial barriers, vaccination services, and behavioral and social supply-side and demand-side factors. China has made significant efforts, however, they may not be sufficient until the inclusion of more WHO-recommended vaccines in the National Immunization Program (NIP), ensuring that the vaccination encompasses the whole life course of individuals, establishment of more trustworthy vaccination finance and procurement, increasing vaccine development, optimizing vaccine demand forecasts, improving the accessibility and equity of vaccination services, capturing the key points of behavioral and social drivers of vaccination on the demand side, and establishing holistic prevention and control from a public health perspective.
世界卫生组织推荐的疫苗可大大预防和控制疫苗可预防疾病（VPDs），但在不同国家和地区的疫苗接种情况有所不同。我们回顾了中国对世界卫生组织推荐疫苗的应用情况，并描述了推动更多疫苗纳入中国国家免疫规划（NIP）所面临的问题和障碍，包括免疫策略、财政障碍、接种服务以及行为和社会供应方和需求方因素。然而，中国已经做出了重大努力，但在更多世界卫生组织推荐疫苗纳入国家免疫规划（NIP）之前，这些努力可能还不够，以确保疫苗接种涵盖个人的整个生命周期，建立更值得信赖的疫苗融资和采购，增加疫苗开发，优化疫苗需求预测，改善疫苗接种服务的可及性和公平性，抓住疫苗接种需求方行为和社会驱动因素的要点，并从公共卫生角度建立全面的预防和控制。
